Skin melanoma represents one of the most common and lethal solid tumor. It usually develops on the skin but it can occur in any tissues with melanine- containing-cells (extracutaneous malignant melanoma). Only 4-5% of malignant melanomas originate in extracutaneous tissues, and they have an extremely lethal behavior (1). These non-skin malignant melanomas are rare but extremely aggressive. Primary melanoma of the genitourinary tract accounts for less than 0.2% of all melanomas. To date only 28 cases of primary bladder melanoma (PMM) are described. We report a rare case of PMM of the bladder in a 72 years old man treated with radical cystectomy and immunotherapy with Nivolumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4081/aiua.2018.3.224 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study.
BMJ Open
December 2024
Wiser Healthcare Research Collaboration, Sydney, New South Wales, Australia
Introduction: A diagnosis of melanoma in situ presents negligible risk to a person's lifespan or physical well-being, but existing terminology makes it difficult for patients to distinguish these from higher risk invasive melanomas. This study aims to explore whether using an alternative label for melanoma in situ may influence patients' management choices and anxiety levels.
Methods And Analysis: This study is a between-subjects randomised online experiment, using hypothetical scenarios.
Genome-wide association studies (GWAS) of melanoma risk have identified 68 independent signals at 54 loci. For most loci, specific functional variants and their respective target genes remain to be established. Capture-HiC is an assay that links fine-mapped risk variants to candidate target genes by comprehensively mapping cell-type specific chromatin interactions.
View Article and Find Full Text PDFSolar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma.
EJC Skin Cancer
December 2024
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Objective: To evaluate the relation between solar elastosis and tumor mutation burden (TMB) in a large clinically annotated cohort of stage II and III melanoma patients.
Methods: Primary cutaneous melanomas from 469 AJCC (8 edition) stage II and III patients with clinical annotation including outcome at 5 years of diagnosis were histopathologically evaluated for solar elastosis. Next-generation sequencing assay MSK-IMPACT was employed to determine TMB.
Primary malignant melanoma of the female urethra: A case report.
Urol Case Rep
January 2025
Wellington Hospital, Capital & Coast, Te Whatu Ora, Wellington, New Zealand.
Primary malignant mucosal melanoma of the female urethra is extremely rare and associated with high recurrence rates and exceptionally poor 5-year survival. Due to its rarity, treatment strategies are heterogenous and often extrapolated from the treatment of other more common types of melanomas. Herein, we describe a case of malignant melanoma of the urethra in a Caucasian female.
View Article and Find Full Text PDFCellMsg: graph convolutional networks for ligand-receptor-mediated cell-cell communication analysis.
Brief Bioinform
November 2024
College of Computer Science and Electronic Engineering, Hunan University, Changsha 410082, China.
The role of cell-cell communications (CCCs) is increasingly recognized as being important to differentiation, invasion, metastasis, and drug resistance in tumoral tissues. Developing CCC inference methods using traditional experimental methods are time-consuming, labor-intensive, cannot handle large amounts of data. To facilitate inference of CCCs, we proposed a computational framework, called CellMsg, which involves two primary steps: identifying ligand-receptor interactions (LRIs) and measuring the strength of LRIs-mediated CCCs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!